|

Camrelizumab (anti-PD-1 inhibitor) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shanghai Jiao Tong University School of Medicine1

Indications

  • Anti-VEGFR1
  • Anti-PD-11
  • Neoadjvant Therapy1
  • Oral Squamous Cell Carcinoma1
  • Cancer1

Other1 trial

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.